Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

US · MD National Institutes of Health (NIH) grant open #PAR-25-446

Response due Aug 21, 2028 · 00:00 UTC

Summary

This NIH funding opportunity (PAR-25-446) supports the development of interventions aimed at preventing and treating substance use disorders (SUD) and overdose. It uses the UG3/UH3 cooperative agreement mechanism, which is a milestone-driven, phased award structure. Clinical trials are optional under this announcement. The opportunity is open for multiple years, accepting applications from September 2025 through August 2028.

What they want

Applicants must propose research to develop, refine, and/or test interventions designed to prevent and/or treat substance use disorders and overdose. Awards follow the UG3/UH3 cooperative agreement mechanism, which involves an initial milestone-driven planning/development phase (UG3) with a contingent transition to an implementation/efficacy phase (UH3). Clinical trials are permitted but not required. NIH program staff play an active collaborative role in the funded projects.

Technical requirements

UG3/UH3 phased cooperative agreement mechanism
Clinical trial component is optional
Milestone-driven phased research design required

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

No dollar value or award ceiling disclosed
Multi-year open window (2025–2028) may obscure specific application deadlines — individual due dates per cycle should be verified in the full FOA

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

Development of Interventions to Prevent an…

Due Aug 21

Onboard ↗